Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis.

American journal of hematology - 1 Apr 2011

Pardanani Animesh, Begna Kebede, Finke Christy, Lasho Terra, Tefferi Ayalew

Abstract excerpt

Cytokine-phenotype associations have recently been described in primary myelofibrosis and increased levels of IL-8, sIL-2R, IL-12, and IL-15 were found to be independently predictive of inferior survival. Pomalidomide therapy is effective for alleviating anemia in myelofibrosis; we examined the relationship between plasma cytokine/chemokine levels and response to treatment with pomalidomide. The study population...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Chemokine CCL2
Share to Interleukin-15

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-8

Share to Janus Kinase 1

Share to Primary Myelofibrosis

Share to Receptors, Interleukin-2

Share to Thalidomide

Source

Identifiers

PMID: 21442636
DOI: 10.1002/ajh.21972

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis.PMID 21442636Read ↗

A phase-2 trial of low-dose pomalidomide in myelofibrosis.Semantic proximity Read ↗

Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.Semantic proximity Read ↗

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.Semantic proximity Read ↗

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.Semantic proximity Read ↗

Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.Semantic proximity Read ↗

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.Semantic proximity Read ↗

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.Semantic proximity Read ↗

Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis.Semantic proximity Read ↗

Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.Semantic proximity Read ↗

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.Semantic proximity Read ↗

Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival.Semantic proximity Read ↗

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.